

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT
EFFECTIVE DATE:	05/31/2005

**CONVEYING PARTY DATA**

Name	Execution Date
Metagenics, Inc.	05/31/2005
Metagenics Far East, Inc.	05/31/2005
Meta Proteomics, L.L.C.	05/31/2006

**RECEIVING PARTY DATA**

Name:	Comerica Bank
Street Address:	333 Santa Clara Ave
City:	San Jose
State/Country:	CALIFORNIA
Postal Code:	95113

**PROPERTY NUMBERS Total: 57**

Property Type	Number
Patent Number:	6733793
Patent Number:	5270297
Patent Number:	5164384
Patent Number:	5626883
Patent Number:	5531988
Patent Number:	5531989
Patent Number:	5744134
Patent Number:	6447809
Patent Number:	6534086
Patent Number:	6180099
Patent Number:	6528502
Patent Number:	5637324

CH \$2280.00 6733793

Patent Number:	6210701
Patent Number:	6602517
Patent Number:	6352712
Patent Number:	5629023
Patent Number:	6432453
Patent Number:	6051260
Patent Number:	6241983
Application Number:	10484123
Application Number:	08331140
Application Number:	08437316
Application Number:	09524416
Application Number:	09885721
Application Number:	09919506
Application Number:	10008778
Application Number:	10056858
Application Number:	10062749
Application Number:	10198277
Application Number:	10241616
Application Number:	10251361
Application Number:	10280198
Application Number:	10282236
Application Number:	10352388
Application Number:	10378572
Application Number:	10400293
Application Number:	10401283
Application Number:	10464410
Application Number:	10464834
Application Number:	10480145
Application Number:	10689856
Application Number:	10735526
Application Number:	10774048
Application Number:	10789814
Application Number:	10789817
Application Number:	10846948
Application Number:	10866315

Application Number:	10988392
Application Number:	60265908
Application Number:	60266269
Application Number:	60306055
Application Number:	60316685
Application Number:	60335062
Application Number:	60352016
Application Number:	60432689
Application Number:	60450237
Application Number:	60555438

**CORRESPONDENCE DATA**

Fax Number: (313)496-8454  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 3139636420  
Email: schultz@millercanfield.com  
Correspondent Name: Joni M. Thrower  
Address Line 1: 150 West Jefferson Ave  
Address Line 4: Detroit, MICHIGAN 48336

ATTORNEY DOCKET NUMBER:	COMERICA METAGENIC-PATENT
NAME OF SUBMITTER:	Joni M. Thrower

Total Attachments: 10  
source=scanned#page1.tif  
source=scanned#page2.tif  
source=scanned#page3.tif  
source=scanned#page4.tif  
source=scanned#page5.tif  
source=scanned#page6.tif  
source=scanned#page7.tif  
source=scanned#page8.tif  
source=scanned#page9.tif  
source=scanned#page10.tif

**INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This Intellectual Property Security Agreement (this "IP Agreement") is made as of May \_\_, 2005, ("Effective Date") by and among Metagenics, Inc., a California corporation, Metagenics Far East, Inc., a Delaware corporation, and Meta Proteomics, LLC, a California limited liability company (individually and collectively, "Grantor"), and Comerica Bank ("Bank").

RECITALS

A. Bank may make advances of money and extend other financial accommodations to Metagenics, Inc. ("Borrower") pursuant to a certain Credit Agreement dated as of May \_\_, 2005 between Borrower and Bank, as amended from time to time (the "Credit Agreement"). Bank is willing to enter into the Credit Agreement, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in certain Copyrights, Trademarks and Patents, and other assets, to secure the obligations of Borrower under the Credit Agreement. In this IP Agreement, capitalized terms used without separate definition have the meanings given to them in the Credit Agreement.

B. Pursuant to the terms of the Credit Agreement, Grantor has granted or has agreed to grant to Bank a security interest in all of Grantor's existing and future right, title, and interest in, to and under all of the Collateral.

For good and valuable consideration, receipt of which is hereby acknowledged and intending to be legally bound, Grantor represents, warrants, covenants and agrees as follows:

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of the Obligations, each person comprising Grantor hereby grants to Bank a security interest and mortgage in all of its right, title and interest in, to and under its registered and unregistered intellectual property collateral (collectively, "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof of Grantor, whether published or unpublished, registered or unregistered, and whether or not the same also constitutes a trade secret, whether now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secret rights, including any rights to unpatented inventions, know-how, operating manuals, license rights and agreements, and confidential information owned by Grantor, and any and all intellectual property rights in computer software and computer software products, whether now or hereafter existing, and created, acquired or owned by Grantor;

(c) Any and all design rights owned by Grantor now or hereafter existing, created, acquired or held by Grantor;

(d) All patents, patent applications and like protections owned by Grantor now or hereafter existing, created, acquired or held by Grantor including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and service mark rights, slogans, trade dress, and trade names, trade styles, whether registered or not, applications to register and registrations of the same and like protections, now or hereafter existing, created, acquired or held by Grantor and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(f) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, including in the Intellectual Property Collateral, the right, without imposing on Bank any obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(g) All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights, including, without limitation those set forth on Exhibit D attached hereto;

(h) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks or Patents; and

(i) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

2. Authorization and Request. Grantor authorizes and requests that the Register of Copyrights and the Commissioner of Patents and Trademarks record this IP Agreement, and any amendments thereto, or copies thereof, or any separate instrument Grantor executes and delivers to Bank to evidence the grant of security interest hereunder.

3. Covenants and Warranties. Grantor represents, warrants, covenants and agrees as follows:

(a) Grantor is now the sole owner of the Intellectual Property Collateral, except for nonexclusive licenses granted by Grantor to its customers and resellers in the ordinary course of business.

(b) Performance of this IP Agreement does not conflict with or result in a breach of any material agreement to which Grantor is party or by which Grantor is bound, except to the extent that certain intellectual property agreements prohibit the assignment of the rights thereunder to a third party without the licensor's or other party's consent and this IP Agreement constitutes an assignment;

(c) During the term of this IP Agreement, Grantor will not transfer or otherwise encumber any interest in the Intellectual Property Collateral, except (i) as permitted in the Credit Agreement, (ii) for non-exclusive licenses granted by Grantor in the ordinary course of business, or (iii) as set forth in this IP Agreement;

(d) Each of the issued Patents that is necessary for the conduct of Grantor's business substantially as now conducted is valid and enforceable, and no part of the Intellectual Property Collateral which had been registered and is necessary for the conduct of Grantor's business substantially as now conducted has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any part of the Intellectual Property Collateral violates the rights of any third party except for such claims which could not reasonably be anticipated to have a Material Adverse Effect;

(e) Grantor shall deliver to Bank within thirty (30) days of the last day of each fiscal quarter, a report signed by Grantor, in form reasonably acceptable to Bank, listing any applications or registrations

that Grantor has made or filed in respect of any patents, copyrights or trademarks and the status of any outstanding applications or registrations. Grantor shall promptly advise Bank of any change in the composition of the Intellectual Property Collateral that could reasonably be expected to have a Material Adverse Effect, and within 30 days of the acquisition thereof, notify Lender of any subsequent ownership right of the Grantor in or to any Trademark, Patent or Copyright specified in this IP Agreement;

(f) Grantor shall use its reasonable efforts to (unless in the judgment of Grantor, it is no longer necessary for the business of the Grantor) (i) protect, defend and maintain the validity and enforceability of the Trademarks, Patents and Copyrights, (ii) detect infringements of the Trademarks, Patents and Copyrights and promptly advise Bank in writing of infringements detected that could reasonably be expected to have a Material Adverse Effect and (iii) not allow, except as permitted under the Credit Agreement, any Trademarks, Patents or Copyrights to be abandoned, forfeited or dedicated to the public without the written consent of Bank, which shall not be unreasonably withheld, unless Grantor determines that reasonable business practices suggest that abandonment is appropriate;

(g) Grantor shall register or cause to be registered with the United States Patent and Trademark Office ("USPTO") or the United States Copyright Office ("USCO"), as applicable, those additional intellectual property rights developed or acquired by Grantor from time to time in connection with any product prior to the sale or licensing of such product to any third party (including without limitation revisions or additions to the intellectual property rights listed on such Exhibits A, B, C and D). Grantor shall, from time to time, execute and file such other instruments, and take such further actions as Bank may reasonably request from time to time, and Grantor hereby authorizes Bank to file any such instruments and take any such further actions, to perfect or continue the perfection of Bank's interest in the Intellectual Property Collateral (including without limitation filings with USPTO or USCO, as applicable);

(h) This IP Agreement creates, and in the case of after-acquired Intellectual Property Collateral, this IP Agreement will create at the time Grantor first has rights in such after-acquired Intellectual Property Collateral, in favor of Bank a valid and perfected first priority security interest and collateral assignment in the Intellectual Property Collateral in the United States securing the payment and performance of the Indebtedness upon making the filings referred to in clause (i) below;

(i) To its knowledge, except for, and upon, the filing of UCC financing statements, filings with the USPTO or the USCO, and other notice filings or notations in appropriate filing offices, if necessary to perfect the security interests created hereunder, no authorization, approval or other action by, and no notice to or filing with, any United States governmental authority or United States regulatory body is required either (i) for the grant by Grantor of the security interest granted hereby, or for the execution, delivery or performance of this IP Agreement by Grantor in the U.S. or (ii) for the perfection in the United States or the exercise by Bank of its rights and remedies hereunder;

(j) All information heretofore or herein supplied to Bank by or on behalf of Grantor with respect to the Intellectual Property Collateral is accurate and complete in all material respects;

(k) Grantor shall not enter into any agreement that would impair or conflict with Grantor's obligations hereunder without Bank's prior written consent, which consent shall not be unreasonably withheld. Grantor shall not permit the inclusion in any material contract to which it becomes a party of any provisions that prevent the creation of a security interest in any of Grantor's rights and interests in any property included within the definition of the Collateral acquired under such contracts, except that certain contracts may contain anti-assignment provisions that could in effect prohibit the creation of a security interest in such contracts if Grantor is required, in its commercially reasonable judgment to accept such provisions; and

(l) Upon any executive officer of Grantor obtaining knowledge thereof, Grantor will promptly notify Bank in writing of any event that materially adversely affects the value of any Intellectual Property Collateral, the ability of Grantor to dispose of any Intellectual Property Collateral or the rights and remedies of Bank in relation thereto, including the levy of any legal process against any of the Intellectual Property Collateral. In the event of a disposition of any Intellectual Property as permitted under the Credit Agreement, Grantor's obligation will be to provide such notices as are required therein.

4. Bank's Rights. Bank shall have the right, but not the obligation, to take, at Grantor's sole expense, any actions that Grantor is required under this IP Agreement to take but which Grantor fails to take, after fifteen (15) days' written notice to Grantor. Grantor shall reimburse and indemnify Bank for all reasonable costs and reasonable expenses incurred in the reasonable exercise of its rights under this Section 4.

5. Inspection Rights. Grantor hereby grants to Bank and its employees, representatives and agents the right to visit, during regular business hours upon prior reasonable written notice to Grantor and as often as may be reasonably requested, any of such Grantor's plants and facilities that manufacture, install or store products (or that have done so during the prior six-month period) that are sold utilizing any of the Intellectual Property Collateral, and to inspect the products and quality control records relating thereto during regular business hours upon reasonable notice to Grantor and as often as may be reasonably requested.

6. Further Assurances; Attorney in Fact.

(a) On a continuing basis, Grantor will, upon the reasonable request by Bank, subject to any prior licenses, encumbrances and restrictions and prospective licenses, make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings with the USPTO and the USCO, and take all such action as may reasonably be deemed necessary or advisable, or as reasonably requested by Bank, to perfect Bank's security interest in all Copyrights, Patents and Trademarks, and otherwise to carry out the intent and purposes of this IP Agreement, or for assuring and confirming to Bank the grant or perfection of a security interest in all Intellectual Property Collateral.

(b) In addition to Section 5(a) above, Grantor shall not register any of its Copyrights or Mask Works with the Register of Copyrights without first executing and simultaneously registering an IP Agreement, in the identical form of this IP Agreement, with the Register of Copyrights, listing such Copyrights(s) on Exhibit A thereto in order to protect and perfect Bank's security interest in such Copyrights. Promptly after such registration, Grantor shall forward to the Bank, at the address listed above, a copy of, and the original IP Agreement as filed with the Register of Copyrights.

(c) Grantor hereby irrevocably appoints Bank as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, Bank or otherwise, from time to time in Bank's discretion, upon Grantor's failure or inability to do so, after written request by Bank, to take any action and to execute any instrument which Bank may reasonably deem necessary or advisable to accomplish the purposes of this IP Agreement, including:

(i) To modify, in its sole discretion, without first obtaining Grantor's approval of or signature to such modification, Exhibit A, Exhibit B, and Exhibit C hereof, as appropriate, to include reference to any right, title or interest in any Copyrights, Patents or Trademarks acquired by Grantor after the execution hereof or to delete any reference to any right, title or interest in any

Copyrights, Patents or Trademarks in which Grantor no longer has or claims any right, title or interest;

(ii) To file, in its sole discretion, one or more financing or continuation statements and amendments thereto, or other notice filings or notations in appropriate filing offices, relative to any of the Intellectual Property Collateral, with notice to, but without the consent of, Grantor, with all appropriate jurisdictions, as Bank deems appropriate, in order to further perfect or protect Bank's interest in the Intellectual Property Collateral; and

(iii) After the occurrence of an Event of Default, to transfer the Intellectual Property Collateral into the name of Bank or a third party to the extent permitted under the California Uniform Commercial Code.

7. Events of Default. The occurrence of an Event of Default under the Credit Agreement shall constitute an Event of Default under this IP Agreement

8. Remedies. Upon the occurrence and continuance of an Event of Default, Bank shall have the right to exercise all the remedies of a secured party under the California Uniform Commercial Code, including without limitation the right to require Grantor to assemble the Intellectual Property Collateral and any tangible property in which Bank has a security interest and to make it available to Bank at a place designated by Bank. Bank shall have a nonexclusive, royalty free license to use the Copyrights, Patents and Trademarks to the extent reasonably necessary to permit Bank to exercise its rights and remedies upon the occurrence of an Event of Default. Grantor will pay any expenses (including reasonable attorney's fees) incurred by Bank in connection with the exercise of any of Bank's rights hereunder, including without limitation any expense incurred in disposing of the Intellectual Property Collateral. All of Bank's rights and remedies with respect to the Intellectual Property Collateral shall be cumulative.

9. Indemnity. Grantor will indemnify, defend and hold harmless Bank and its officers, employees, and agents against: (a) obligations, demands, claims, and liabilities asserted by any other party in connection with the transactions contemplated by this IP Agreement; and (b) losses or expenses incurred, or paid by Bank as a result of or in any way arising out of, following or consequential to transactions between Bank and Grantor (including without limitation reasonable attorneys' fees and expenses), except for losses arising from or out of Bank's gross negligence or willful misconduct.

10. Course of Dealing. No course of dealing, nor any failure to exercise, nor any delay in exercising any right, power or privilege hereunder shall operate as a waiver thereof.

11. Attorneys Fees. If any action relating to this Agreement is brought by either party hereto against the other party, the prevailing party shall be entitled to recover reasonable attorneys' fees, costs and disbursements.

12. Amendments. This IP Agreement may be amended only by a written instrument signed by all parties hereto.

13. Counterparts. This IP Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.

14. California Law and Jurisdiction; Jury Waiver. This IP Agreement shall be governed by the laws of the State of California, without regard for choice of law provisions. Grantor and Secured Party consent to the exclusive jurisdiction of any state or federal court located in California. GRANTOR AND SECURED PARTY EACH WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF



ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THE LOAN DOCUMENTS, THIS IP AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS.

15. Termination. At such time as Grantor shall completely satisfy all of the obligations secured hereunder, Bank shall execute and deliver to Grantor and the appropriate registration/recording authorities, all releases, terminations, and other instruments as may be necessary or proper to release the security interest hereunder.<sup>1</sup>

[signatures on the following page]

---

<sup>1</sup> This section was not in the original agreement.


This Intellectual Property Security Agreement is executed and delivered as of the Effective Date.

ADDRESS OF GRANTOR:


100 Avenida La Pata  
San Clemente, CA 92673

GRANTOR:


METAGENICS, INC.

By:   
Name: JERRY H. MOREY  
Title: CEO

METAGENICS FAR EAST, INC.

By:   
Name: JERRY H. MOREY  
Title: CEO

META PROTEOMICS, LLC

By:   
Name: JERRY H. MOREY  
Title: CEO

Metaproteomics	CURCUMINOID COMPOSITIONS EXHIBITING SYNERGISTIC INHIBITION OF THE EXPRESSION AND/OR ACTIVITY OF CYCLOOXYGENASE-2 [WITH HOPSI]	10/484,123
Metagenics	BACTERIA AND IMMUNOGLOBULIN-CONTAINING COMPOSITION FOR HUMAN GASTROINTESTINAL HEALTH	08/331,140
Metagenics	IMMUNOGLOBULIN AND FIBER-CONTAINING COMPOSITION FOR HUMAN GASTROINTESTINAL HEALTH	08/437,316
Metaproteomics	ANTI-INFLAMMATORY & CONNECTIVE TISSUE REPAIR FORMULATIONS	09/524,416
Metaproteomics	COMPLEX MIXTURES EXHIBITING SELECTIVE INHIBITION OF CYCLOOXYGENASE-2 [HOPS EXTRACT ALONE]	09/885,721
Metaproteomics	COMBINATIONS OF SESQUITERPENE LACTONES AND DITERPENE LACTONES OR TRITERPENES FOR SYNERGISTIC INHIBITION OF CYCLOOXYGENASE-2	09/919,506
Metaproteomics	NOVEL ANTI-INFLAMMATORY CYCLOOXYGENASE INHIBITORS	10/008,778
Metagenics	MEDICAL FOOD FOR MANAGING HORMONE BALANCE	10/056,858
Metagenics	COATING FOR ORALLY ADMINISTERED COMPOSITIONS	10/062,749
Metaproteomics	CURCUMINOID COMPOSITIONS EXHIBITING SYNERGISTIC INHIBITION OF THE EXPRESSION AND/OR ACTIVITY OF CYCLOOXYGENASE-2 [WITH HOPSI]	10/198,277
Metagenics	COMPOSITION FOR PROMOTING HEALTHY BONE STRUCTURE	10/241,616
Metaproteomics	ANTI-INFLAMMATORY & CONNECTIVE TISSUE REPAIR FORMULATIONS	10/251,361
Metaproteomics	COMPLEX MIXTURES EXHIBITING SELECTIVE INHIBITION OF CYCLOOXYGENASE-2 [HOPS EXTRACT ALONE]	10/280,198
Metaproteomics	CURCUMINOID COMPOSITIONS EXHIBITING SYNERGISTIC INHIBITION OF THE EXPRESSION AND/OR ACTIVITY OF CYCLOOXYGENASE-2 [WITH HOPSI]	10/282,236
Metagenics	MEDICAL COMPOSITION FOR BALANCING BODILY PROCESSES	10/352,388
Metagenics	COMPOSITION AND METHOD FOR TREATMENT OF INFLAMMATION AND PAIN IN MAMMALS	10/378,572
MetaProteomics	MODULATION OF NF-KB BY HOPS FRACTIONS AND DERIVATIVES	10/400,293
MetaProteomics	SYNERGISTIC COMPOSITIONS ASSOCIATED WITH TISSUE-SPECIFIC ACTIVATION OF NF-KB	10/401,283
Metaproteomics	SYNERGISTIC COMPOSITIONS THAT TREAT OR INHIBIT PATHOLOGICAL CONDITIONS ASSOCIATED WITH INFLAMMATORY RESPONSE	10/464,410
Metaproteomics	MODULATION OF INFLAMMATION BY HOPS FRACTIONS & DERIVATIVES	10/464,834

COMPLEX MIXTURES EXHIBITING SELECTIVE INHIBITION OF CYCLOOXYGENASE-2		
Metaproteomics	COMPOSITIONS THAT TREAT OR INHIBIT PATHOLOGICAL CONDITIONS ASSOCIATED WITH INFLAMMATORY RESPONSE	10/480,145
Metaproteomics	MEDICAL COMPOSITION FOR BALANCING BODILY PROCESSES	10/689,856
Metagenics	ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATION AND THE TREATMENT OR PREVENTION OF GASTRIC TOXICITY	10/735,526
Metaproteomics	SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE	10/774,048
Metaproteomics	ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLYXANTHINES	10/789,814
Metagenics	ENCAPSULATED FRACTIONS ISOLATED OR DERIVED FROM HOPS	10/789,817
Metaproteomics	5-LOX INHIBITOR PATENT APPLICATION	10/846,948
Metaproteomics	COMPOSITIONS EXHIBITING INHIBITION OF CYCLOOXYGENASE-2 (68911-0092)	10/866,315
MetaProteomics	MEDICAL FOOD FOR MANAGING HORMONE BALANCE	10/988,392
Metagenics	COATING FOR ORALLY ADMINISTERED COMPOSITIONS	60/265,908
Metagenics	CURCUMINOID COMPOSITIONS EXHIBITING SYNERGISTIC INHIBITION OF THE EXPRESSION AND/OR ACTIVITY OF CYCLOOXYGENASE-2 [WITH HOPS]	60/266,269
Metaproteomics	ARGININE COMPOSITIONS FOR COORDINATE MODIFICATION OF MULTIPLE CARDIOVASCULAR RISK FACTORS	60/306,055
Metaproteomics	CURCUMINOID COMPOSITIONS EXHIBITING SYNERGISTIC INHIBITION OF THE EXPRESSION AND/OR ACTIVITY OF CYCLOOXYGENASE-2 [WITH HOPS]	60/316,685
Metaproteomics	HOPS]	60/335,062
Metagenics	MEDICAL COMPOSITION FOR BALANCING BODILY PROCESSES	60/352,016
Metagenics	OPTIMIZATION OF ESTROGENIC HORMONE LEVELS	60/432,689
Metaproteomics	ANTI-INFLAMMATORY COMPOSITIONS CONTAINING HOPS FRACTIONS OR DERIVATIVES EXHIBITING LOW GASTROINTESTINAL IRRITATION	60/450,237
Metagenics	METHODS FOR TREATMENT OF ESTROGEN RELATED CONDITIONS	60/555,438
Metaproteomics	AN ORAL COMPOSITION WITH INSULIN-LIKE ACTIVITIES AND METHODS OF USE	6,733,793
Metagenics	IMPROVED ENDURANCE & REHYDRATION COMPOSITION	5270297
Metagenics	ANABOLIC MINERAL FORMULA	5164384
Metagenics	ASCORBIC ACID COMPOSITION PROVIDING ENHANCED HUMAN IMMUNE SYSTEM ACTIVITY	5626883
Metagenics	COMPOSITION AND METHOD FOR HUMAN GASTROINTESTINAL HEALTH	5531988
Metagenics	COMPOSITION AND METHOD FOR HUMAN GASTROINTESTINAL HEALTH	5531989

Metagenics	COMPOSITION AND METHOD FOR HUMAN GASTROINTESTINAL HEALTH	5744134
Metagenics	COMPOSITION FOR PROMOTING HEALTHY BONE STRUCTURE	6447809
Metagenics	PAIN IN MAMMALS	6534086
Metagenics	COMPOSITION AND METHOD FOR HUMAN GASTROINTESTINAL HEALTH	6,180,099 B1
Metagenics	COMPOSITION AND METHOD FOR IMPROVING CARBOHYDRATE	
Metagenics	MANAGEMENT IN MAMMALS	6528502
Metagenics	MEDICAL FOOD COMPOSITION FOR METABOLIC DETOXIFICATION	5637324
Metagenics	MEDICAL FOOD FOR TREATING INFLAMMATION-RELATED DISEASES	6210701
Metagenics	MEDICAL FOOD FOR TREATING INFLAMMATION-RELATED DISEASES	6,602,517 B2
Metagenics	DIETARY SUPPLEMENTS FOR TREATING FATIGUE-RELATED SYNDROMES	6352712
Metagenics	MEDICAL FOOD COMPOSITION FOR METABOLIC DETOXIFICATION	5629023
Metagenics	DIETARY SUPPLEMENT CONTAINING GLYCEROL ESTER OF CONJUGATED	
Metagenics	LINOLEIC ACID AND ROSEMARY EXTRACT CONTAINING CARNOSIC ACID	6432453
Metagenics	MEDICAL FOOD COMPOSITION OF REDUCED ALLERGENICITY,	
Metagenics	ESPECIALLY ADAPTED FOR IMPROVING GUT MUCOSAL INTEGRITY	6051260
Metagenics	COMPOSITION AND METHOD FOR HUMAN GASTROINTESTINAL HEALTH	6241983